Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 2/20 | 0.41 |
| ▸ | KDR | P35968 | 2/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | PRMT6 | Q96LA8 | 5/20 | 0.40 |
| ▸ | ASH1L | Q9NR48 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | AAK1 | Q2M2I8 | 5/20 | 0.38 |
| ▸ | CHUK | O15111 | 1/20 | 0.37 |
| ▸ | INSR | P06213 | 1/20 | 0.37 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.37 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.37 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | GAK | O14976 | 4/20 | 0.36 |
| ▸ | STK16 | O75716 | 4/20 | 0.36 |
| ▸ | BMP2K | Q9NSY1 | 4/20 | 0.36 |
| ▸ | CDKL2 | Q92772 | 2/20 | 0.36 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.36 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.36 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3206330 | 0.89 | PDGFRB (0.42) | PDGFRBKDRPARP1AAK1CHUK | |
| SCHEMBL3197247 | 0.89 | DHODH (0.48) | PDGFRBKDRAAK1CHUKINSR | |
| SCHEMBL3204674 | 0.89 | DHODH (0.41) | PDGFRBKDRPARP1AAK1CHUK | |
| SCHEMBL3205994 | 0.88 | PARP1 (0.43) | PDGFRBKDRPARP1AAK1CHUK | |
| SCHEMBL9884417 | 0.88 | FGFR2 (0.44) | PDGFRBKDRAAK1CHUKINSR | |
| SCHEMBL3835837 | 0.87 | PARP1 (0.40) | PDGFRBKDRPARP1ASH1LNOS1 | |
| Hydrochloric Acid SCHEMBL3831155 | 0.87 | FGFR2 (0.43) | PDGFRBKDRCHUKINSRMAPK8 | |
| SCHEMBL3206896 | 0.86 | VSIR (0.39) | PDGFRBKDRAAK1CHUKINSR | |
| SCHEMBL3215920 | 0.86 | CHUK (0.51) | PDGFRBKDRPARP1CHUKINSR | |
| SCHEMBL3193888 | 0.86 | ACMSD (0.42) | PDGFRBKDRPARP1AAK1CHUK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2119703-B1 | NOVEL INDOLE DERIVATIVE HAVING INHIBITORY ACTIVITY ON I B KINASE | SANTEN PHARMACEUTICAL CO LTD (JP) | 2012-12-12 | — | — | EP | disclosed |
| US-8193237-B2 | Indole derivative having IκB kinase β inhibitory activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2012-06-05 | — | — | US | disclosed |
| US-8193237-B2 | Indole derivative having IκB kinase β inhibitory activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2012-06-05 | — | — | US | disclosed |
| US-8193237-B2 | Indole derivative having IκB kinase β inhibitory activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2012-06-05 | — | — | US | disclosed |
| US-20100041628-A1 | NOVEL INDOLE DERIVATIVE HAVING IKAPPAB KINASE BETA INHIBITORY ACTIVITY | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-02-18 | — | — | US | disclosed |
| US-20100041628-A1 | NOVEL INDOLE DERIVATIVE HAVING IKAPPAB KINASE BETA INHIBITORY ACTIVITY | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-02-18 | — | — | US | disclosed |
| US-20100041628-A1 | NOVEL INDOLE DERIVATIVE HAVING IKAPPAB KINASE BETA INHIBITORY ACTIVITY | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-02-18 | — | — | US | disclosed |
| EP-2119703-A1 | NOVEL INDOLE DERIVATIVE HAVING INHIBITORY ACTIVITY ON I B KINASE | Santen Pharmaceutical Co., Ltd (JP) | 2009-11-18 | — | — | EP | disclosed |
| EP-2119703-A1 | NOVEL INDOLE DERIVATIVE HAVING INHIBITORY ACTIVITY ON I B KINASE | Santen Pharmaceutical Co., Ltd (JP) | 2009-11-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041628-A1 | NOVEL INDOLE DERIVATIVE HAVING IKAPPAB KINASE BETA INHIBITORY ACTIVITY | NFKBIA, IKBKB, IKBKG | PDGFRB 2002/4885KDR 2911/4885PARP1 2812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.